Coherus BioSciences Inc. (CHRS)

NASDAQ: CHRS · Real-Time Price · USD

1.03

0.00 (0.00%)

At close: May 01, 2025, 3:59 PM

1.04

0.48%

After-hours: May 01, 2025, 05:33 PM EDT

0.00% (1D)

Bid	1.01
Market Cap	119.95M
Revenue (ttm)	266.96M
Net Income (ttm)	28.51M
EPS (ttm)	0.25
PE Ratio (ttm)	4.14
Forward PE	-1.02
Analyst	Buy

Ask	1.04
Volume	1,016,745
Avg. Volume (20D)	1,770,259
Open	1.01
Previous Close	1.03
Day's Range	0.99 - 1.05
52-Week Range	0.66 - 2.43
Beta	1.01

About CHRS

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 6, 2014

Employees 228

Stock Exchange NASDAQ

Ticker Symbol CHRS

Website https://www.coherus.com

Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for CHRS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 576.33% from the latest price.

Stock Forecasts

Next Earnings Release

Coherus BioSciences Inc. is scheduled to release its earnings on May 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+16.59%

Coherus BioSciences shares are trading higher afte... Unlock content with Pro Subscription

5 months ago

+24.82%

Coherus Biosciences shares are trading higher after the company announced an agreement to divest its Udenyca franchise for $558.4 million.

News

2 weeks ago · seekingalpha.com

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep...

1 month ago · seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok...